Cargando…

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

OBJECTIVE: To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kappos, Ludwig, O'Connor, Paul, Radue, Ernst-Wilhelm, Polman, Chris, Hohlfeld, Reinhard, Selmaj, Krzysztof, Ritter, Shannon, Schlosshauer, Rolf, von Rosenstiel, Philipp, Zhang-Auberson, Lixin, Francis, Gordon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408283/ https://www.ncbi.nlm.nih.gov/pubmed/25795646 http://dx.doi.org/10.1212/WNL.0000000000001462

Ejemplares similares

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
por: Vermersch, Patrick, et al.
Publicado: (2017)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
por: Kira, Jun-ichi, et al.
Publicado: (2014)

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
por: Saida, Takahiko, et al.
Publicado: (2017)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2015)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Fingolimod in children with Rett syndrome: the FINGORETT study
por: Naegelin, Yvonne, et al.
Publicado: (2021)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
por: Sprenger, Till, et al.
Publicado: (2019)

Fingolimod induces neuroprotective factors in human astrocytes
por: Hoffmann, Franziska S., et al.
Publicado: (2015)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
por: Magon, Stefano, et al.
Publicado: (2014)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST)
por: Amann, Michael, et al.
Publicado: (2014)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Practicing intellectual freedom in libraries
por: Oltmann, Shannon M
Publicado: (2019)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
por: Kendler, D. L., et al.
Publicado: (2018)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Freedom of the will /
por: Edwards, Jonathan, 1703-1758
Publicado: (1969)

Freedom /
por: Franzen, Jonathan

Freedom
Publicado: (1890)

Cannot write session to /tmp/vufind_sessions/sess_s4b0al0vup5b6abgeujs0n5lmj